NHS to use world-first ‘subscription-style’ model to tackle AMR

NHS to use world-first ‘subscription-style’ model to tackle AMR

Contracts are set to be offered to pharmaceutical companies, paying them at the beginning of their work, in order to incentivise work in bringing new antibiotics to market which could counteract antimicrobial resistance (AMR).

As part of the deals, of which the NHS reportedly has two contracts ready to offer, the healthcare service would secure access to the innovative treatments, with NHS patients potentially able to benefit from them as early as 2022.

It will represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases. Of particular interest are antibiotics which can provide alternative treatments for serious infections, such as bloodstream infections, sepsis and hospital-acquired pneumonia.

Often, the high costs and low returns associated with antibiotic research and development make it a commercially unattractive enterprise for the pharmaceutical industry, prompting the unique ‘subscription-style’ payment model approach the UK government is taking in this instance.

Health Secretary Matt Hancock said: “The incredible discovery of antibiotics nearly 100 years ago transformed the health of our nation and our ability to combat infections. Diseases that were once a death sentence are now treated in just one small step.

“But resistance to antibiotics is increasing and it’s imperative we take urgent action on a national and global scale to protect future generations.

“This new way of buying antibiotics for patients in the NHS breaks down restrictive barriers to offer companies a vital springboard to foster innovation and develop potentially life-saving new products.”

The contracts represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases

The contracts represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance, added: “Antibiotics underpin modern medicine and are integral for global health security. Governments and industry must work together to produce new antibiotics and ensure that we can continue to treat common diseases.

“The UK is leading the way by encouraging companies to produce new antibiotics to stay one step ahead of life-threatening diseases.”

The payment model, which was launched back in July 2019, will pay pharmaceutical companies upfront for access to their antibiotic product, based on a product’s value to the NHS, rather than how much is used.

This aims to incentivise companies to invest in researching and developing new antibiotics, helping secure much-needed alternative treatment options for NHS patients.

Two drugs which have proven to be both safe and effective during trials will then be selected to undergo health technology assessment (HTA) by NICE throughout 2021 using adapted methods for antimicrobials. The HTA will be used to decide the level of the subscription payment.

From this week, suppliers can register their interest for the scheme on NHS England’s eTendering Service.

NHE Sep/Oct 20

NHE Sep/Oct 20

Building notes, business cases and the next generation.

Click here to read the Sep/Oct issue of NHE magazine, as we delve intothis issues key topis including; digital innovation, estates and facilities, and training and development. 

Videos...

View all videos
Pager

Survey

Where are you on your pager replacement journey?

Here at NHE, we're investigating how the NHS is responding to the phase-out of pagers in hospitals.

Take out short survey - to thank you for your time, we'll enter you into a prize draw to win a £50 Amazon voucher.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all